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Coexpression of ER with ER and Progestin Receptor
Proteins in the Female Rat Forebrain: Effects of
Estradiol Treatment
BE´ATRICE GRE´CO, E. A. ALLEGRETTO, M. J. TETEL, AND J. D. BLAUSTEIN
Center for Neuroendocrine Studies, University of Massachusetts (B.G., M.J.T., J.D.B.), Amherst, Massachusetts 01003; and
DuPont Pharmaceuticals Co. (E.A.A.), Wilmington, Delaware 19880
Estrogen and progestin receptors (ER, PgR) play a critical
role in the regulation of neuroendocrine functions in females.
The neuroanatomical distribution of the recently cloned,
ER, overlaps with both ER and PgR. To determine whether
ER is found within ER- or PgR-containing neurons in fe-
male rat, we used dual label immunocytochemistry. ER-
immunoreactivity (ER-ir) was primarily detected in the nu-
clei of cells in the periventricular preoptic area (PvPO), the
bed nucleus of the stria terminalis (BNSTpr), the paraven-
tricular nucleus, the supraoptic nucleus, and the medial
amygdala (MEApd). Coexpression of ER-ir with ER-ir or
PgR-ir was observed in the PvPO, BNSTpr, and MEApd in
ovariectomized rats. E2 treatment decreased the number of
ER-ir cells in the PvPO and BNSTpr and the number of
ER-ir cells in the MEApd and paraventricular nucleus, and
therefore decreased the number of cells coexpressing ER-ir
and ER-ir in the PvPO, BNSTpr, and MEApd. E2 treatment
increased the amount of PgR-ir in cells of the PvPO, BNSTpr,
and MEApd, a portion of which also contained ER. These
results demonstrate that ER is expressed in ER- or PgR-
containing cells, and they suggest that E can modulate the
ratios of these steroid receptors in a brain region-specific
manner. (Endocrinology 142: 5172–5181, 2001)
ESTROGEN (E) AND PROGESTINS are involved in theregulation of many reproductive functions (1). Al-
though receptors for E (ER) and progestins (PgR) were dis-
covered in the brain of female rats in the 1960s and 1970s, the
more recent discovery of different subtypes and/or isoforms
of these receptors has added another layer of complexity to
the study of steroid signaling in the brain. In particular, the
recently discovered second ER, ER (2–4), is expressed in the
brain of a number of species (5, 6).
ER shares a high level of sequence identity with ER in
some receptor domains, and both receptors bind to estradiol
(E2) with similar affinity (7). However, ER and ER can
exhibit different transcriptional activities in cotransfection
experiments depending on the ligands and promoters tested
(8, 9). Furthermore, ER and ER have the ability to ho-
modimerize and heterodimerize and display different tran-
scriptional activities dependent on the particular dimer that
is formed (10, 11). Thus, cellular responses to estrogenic
ligands may depend in part on the presence and ratio of the
ER subtypes. Therefore, to study E signaling in the brain, it
is important to determine the extent of cellular coexpression
of ER and ER in specific neuroanatomical areas.
Recent studies have demonstrated that progesterone can
alter the expression of ER mRNA in human breast tumors
(12) and monkey corpus luteum (13). Additionally, one study
showed that E2 acts through ER to induce PgR expression
in a colon cancer cell line (14). In the brain virtually all cells
in which E2 induces PgR expression contain ER (15). How-
ever, E2 also induces some PgR expression in ER knockout
mice (ERKO). This response could be due to the presence
of residual ER variants (16, 17). Alternatively, ER may
mediate PgR induction upon E2 treatment in the ERKO (17).
To examine whether the presence of ER alters the expres-
sion of PgR in female rat brain, it is essential to first determine
whether ER and PgR are present within the same cells.
ERmRNA has been detected in the brain by both RT-PCR
and in situ hybridization (5, 7). Substantial quantities of ER
mRNA exist in hypothalamic and limbic regions of the brain,
which are known to contain high levels of ER and PgR. ER
mRNA has also been detected in other regions of the brain
[supraoptic nucleus and paraventricular nucleus (PVN)]
known to express little or no ER or PgR (5). Recently, Shugh-
rue et al. (18) also observed the presence of ER-immuno-
reactivity (ER-ir) in ER mRNA-containing neurons of lim-
bic and hypothalamic regions of the female rat brain,
suggesting that in vivo, ER and ER proteins may be ex-
pressed within the same cells. ER protein has also been
detected in rat brain by use of immunocytochemistry (19). In
this study, which used an affinity-purified polyclonal anti-
body raised against the C-terminus of rat ER, ER protein
was seen in a more limited number of cells and in fewer
regions than ER mRNA by in situ hybridization.
In the present study we determined the extent of cellular
coexpression of ER-ir with ER-ir as well as ER-ir with
PgR-ir in different brain regions, using a newly developed
monoclonal antibody raised against a peptide from the N-
terminal region of ER. The resulting distribution of ER-ir
cells closely matched the distribution of cells containing
moderate to high levels of ERmRNA in female rat brain (5).
A double label immunofluorescence technique was used to
Abbreviations: BNSTpr, Bed nucleus of the stria terminalis; E, estro-
gen; E2, estradiol; EB, E2 benzoate; ER-ir, ER-immunoreactivity;
ERKO, ER knockout mice; hER, human ER; MEApd, medial amyg-
dala; OVX, ovariectomized; PgR, progestin receptor; PVN, paraven-
tricular nucleus; PvPO, periventricular preoptic area; TBS, Tris-buffered
saline.
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determine whether ER-ir was present in ER-ir- or PgR-
ir-containing neurons in forebrain regions of ovariectomized
female rats. Moreover, we tested the hypothesis that E2 treat-
ment influenced the distribution and the ratio of coexpres-
sion of these receptors.
Materials and Methods
Animals
Female Sprague Dawley rats (175–200 g; Charles River Laboratories,
Inc. Breeding Laboratories, Inc., Wilmington, MA) were group-housed
for 1 wk in a 14-h light, 10-h dark cycle, with food and water available
ad libitum. Procedures were approved by the institutional animal care
and use committee of the University of Massachusetts (Amherst, MA).
All rats were then ovariectomized (OVX) after ip injections of a cocktail
of xylazine (5 mg/kg), ketamine (26 mg/kg), and acetopromazine (0.9
mg/kg). One week after surgeries, levels of circulating E2 are extremely
low, and a bolus injection of 10g E2 benzoate (EB) restores them within
24 h. Thus, 1 wk later, the experimental group of females was injected
sc with either 10 g EB (n 5) or sesame oil vehicle (0.1 ml; n 5), and
animals were killed 48 h later.
Immunoblotting
Protein extracts were from Sf21 insect cells infected without or with
human (h) ER (1–485) or wild-type hER recombinant virus. Cells were
harvested, washed, and lysed in ice cold buffer containing 0.4 m KCl, 10
mm Tris (pH 7.5), 0.5 mm phenylmethylsulfonylfluoride, 1 g/ml apro-
tinin, and 1 mm dithiothreitol. Soluble protein extracts were obtained by
centrifugation at 100,000 g for 45 min at 4 C. Protein concentration was
determined, and extracts were added to SDS-PAGE buffer, subjected to
SDS-PAGE, and transferred to nitrocellulose membranes (Bio-Rad Lab-
oratories, Inc., Richmond, CA). Membranes were blocked in 5% Car-
nation instant nonfat dry milk in Tris-buffered saline (TBS; Bio-Rad
Laboratories, Inc.) for 15 min. Primary hER antibody (1 g/ml) was
incubated with membranes overnight at room temperature in 0.5% milk
in TBS/0.1% Tween-20. Goat antimouse secondary antibodies conju-
gated to alkaline phosphatase (Bio-Rad Laboratories, Inc.) were incu-
bated with membranes for 2 h at room temperature in 0.5% milk/TBS/
0.1% Tween-20. Washes and development of color were performed
according to the Bio-Rad Laboratories, Inc., protocol.
Characterization of ER and ER antibodies: ligand-bound
vs. unbound receptors
To determine whether variations in ER or ER immunostaining after
E2 treatment may be attributable to differential recognition of ligand-
bound vs. unbound ERs by the respective antibodies, OVX female rats
were injected sc with either 50g 17-E2 dissolved in 0.1 ml vehicle (n
5) or the 50% ethanol-water vehicle (n  5), and they were perfused 20
min later. This treatment with a large amount of free E2 for a short period
of time is believed to induce maximal ligand occupancy of ER without
resulting in down-regulation of the receptor protein (20).
Control for ER down-regulation
To determine whether recognition of the antibody for the receptor is
influenced by binding of EB at the same concentration as that used in
the 48-h experiment and to determine whether any variations in ER or
ER immunostaining at 48 h could be due to ER down-regulation, a
second group of female rats was injected sc with the same dose of EB
as the experimental group (10 g; n  4) or oil vehicle (0.1 ml; n  4),
but they were perfused 2 h later, instead of 48 h later. This treatment is
expected to result in higher levels of circulating E2 (21) and occupation
of ERs (22) than in the 48 h experimental group, but considerably less
than in the group receiving 50 g free E2 20 min before perfusion.
Perfusions
All animals received a lethal dose of sodium pentobarbital (89 mg/
kg), and they were perfused with 0.9% physiological saline (25 ml) for
1 min followed by 4% paraformaldehyde (25 ml/min) for 10 min. After
the brains were removed from the cranium, they were placed into 0.1 m
sodium phosphate buffer (pH 7.2) containing 20% sucrose for 48 h.
Thirty-five-micron sections from the preoptic area to the midbrain re-
gion were cut on a freezing microtome, and the sections were placed into
a cryoprotectant solution.
Double label immunofluorescence for ER-ir with either
ER-ir or PgR-ir
For all animals, two sets of sections were removed from cryopro-
tectant and rinsed three times for 5 min each time in 0.05 m TBS, pH 7.6.
Sections were placed into a solution containing 1% H2O2, 20% normal
goat serum, and 1% BSA for 20 min. Sections were then incubated for
2 d at 4 C in a solution containing the mouse monoclonal hER antibody
(hERNT-221.3, Ligand Pharmaceuticals, Inc., San Diego, CA; 1 g/ml)
raised against a synthetic peptide corresponding to the 14-amino acid
N-terminal sequence of hER (1–485 form) and either the rabbit poly-
clonal rat ER antibody (C1355; gift from M. Shupnik, University of
Virginia, Charlottesville, CA; 1:30,000) raised against the last 14-amino
acid C-terminal sequence of rat ER or the rabbit polyclonal human PgR
antibody (DAKO Corp., Carpinteria, CA; 1:500) raised against a syn-
thetic peptide corresponding to the DNA-binding domain of human PgR
(PgR-A and PgR-B forms; 533–547), in a buffer containing TBS, 0.1%
gelatin, 0.02% sodium azide, 0.5% Triton X-100, and 1% normal goat
serum (TBS-gel). After three washes in TBS-gel buffer, the sections were
incubated in a solution containing the cyanine goat antimouse (7g/ml,
to reveal ER-ir) and the fluorescein goat antirabbit (10 g/ml, to reveal
ER-ir or PgR-ir) secondary antisera for 90 min at room temperature. The
sections were then rinsed three times for 5 min each time in TBS,
mounted onto slides, air-dried, and coverslipped with Vectashield
mounting medium (Vector Laboratories, Inc., Burlingame, CA).
Immunocytochemistry controls
ER-ir preadsorption. To determine the specificity of the anti-ER anti-
body immunostaining for ER, the anti-ER antibody was preadsorbed
at 4 C overnight with a 100-fold molar excess of its corresponding
synthetic peptide before use in the immunostaining assays and was used
to immunostain brain sections.
PgR-ir preadsorption. To determine the specificity of the PgR immuno-
staining, the rabbit anti-PgR antibody was preadsorbed at 4 C overnight
with a 100-fold molar excess of a mix of human PgR-A and PgR-B
recombinant proteins (Tissue Culture Core Facility of the University of
the Colorado Cancer Center) before use in immunostaining.
Double label immunofluorescent controls. To control for nonspecific
immunofluorescent staining, cross-immunoreactivity, and “bleed-
through” of the fluorochromes, sections were also incubated either in
solutions in which the primary antibodies were omitted and the sec-
ondary antibodies were present or in solutions in which only one pri-
mary antibody was present and both secondary antibodies were present.
No nonspecific immunofluorescent staining, cross-immunostaining, or
bleed-through was observed (data not shown).
Data analysis
Quantification of double labeled immunofluorescent cells. Quantifications
were performed on one matched section per brain region for each rat.
Using the NIH Image computer analysis system (developed at the NIH
and available at http://rsb.info.nih.gov/nih-image/), digitized pictures
of the same microscopic field were captured with two different bandpass
filters, specific for cyanine and fluorescein. The images were superim-
posed, and the numbers of single or double labeled cells were counted
by eye in the brain region chosen. Because the main point of the present
study was to report the level of colocalization of ER with either ER
or PgR, the regions examined were selected based upon the presence of
ER-ir cells, that is, in the principal nucleus of the bed nucleus of the stria
terminalis (BNSTpr), the periventricular zone of the preoptic area
(PvPO), the posterodorsal nucleus of the medial amygdala (MEApd),
and PVN. The quantification for all groups was performed with a 10
objective for each brain region (BNSTpr, 340 300 m; PvPO, 580 120
m; MEApd, 870  240 m; PVN, 390  480 m), except for the 2 h
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control groups, in which the quantification was performed with a 20
objective (BNSTpr, 180  160 m; PvPO, 420  90 m; MEApd, 370 
160 m). In all microscopic fields observed, only cells that were clearly
distinguishable were counted.
Variation in PgR immunofluorescent intensity in cells of oil- and EB-treated
females. Many studies have shown that variations in immunostaining
intensity can be measured by variations in OD (mean pixel densities)
(23–25). Using inverted digitized pictures for PgR-ir, the mean pixel
density of PgR-ir was measured in the PvPO, BNSTpr, MEApd, and PVN
in oil- and EB-treated females, as described in detail previously (25). In
brief, the gain and black levels of the camera were set so that the gray
level ranged from 0 to 255 pixel density for PgR immunoreactivity (0
being white and 255 being black). The density threshold was set to
determine the contribution of the background immunoreactivity and to
exclude it from the contribution of the foreground immunoreactivity.
The OD of PgR-ir (i.e. the intensity of PgR immunofluorescence) was
determined for each area and was represented by the average and sem
of the pixel densities of the sections analyzed.
Variation in PgR immunofluorescent intensity in cells coexpressing ER-ir.
PgR-ir was apparent in many cells with or without EB treatment. How-
ever, the OD of PgR-ir in EB-treated females was considerably brighter
(see above, Table 3). Therefore, to determine whether cells in which EB
treatment increased PgR expression contained ER-ir, the darkly im-
munostained PgR neurons were counted in EB-treated females using a
method similar to that described above. The density threshold was set
to eliminate E2-independent PgR immunoreactivity in oil-treated fe-
males, and was used to measure foreground PgR immunoreactivity in
EB-treated females. Processed images were superimposed on corre-
sponding digitized pictures containing ER-ir, and the darkly immu-
nostained PgR neurons coexpressing ER-ir were counted by eye in the
PvPO, BNSTpr, and MEApd.
Statistical analysis. t tests with P 0.05 were used to determine statistical
difference in the mean number of labeled cells per brain regions and in
the mean percent colocalization of steroid receptors in labeled cells per
brain regions.
Results
Specificity of ER antibody
Immunoblotting was used to test the specificity of the ER
antibody used in the immunostaining studies. An immuno-
reactive band of the predicted molecular mass of ER (55
kDa) was observed on blots probed with the ER antibody
in lanes containing protein extract from insect cells infected
with hER recombinant virus, but not in lanes containing
extracts from mock- or hER-infected cells (Fig. 1A). There-
fore, this antipeptide ER monoclonal antibody reacts with
ER, but not with ER, on a Western blot. Additionally, this
antibody reacted with ligand-occupied ER, but not with
holo-ER, as assessed by ligand binding immunoprecipita-
tion of the recombinant proteins (data not shown).
FIG. 1. A, Immunodetection of hER,
but not hER, with the anti-ERmono-
clonal antibody. Total soluble protein
extracts (10 g) from noninfected Sf21
cells (lane 3) or from Sf21 cells infected
with hER-(1–485) (lane 1), or hER
(lane 2) were electrophoresed via SDS-
PAGE and transferred to nitrocellulose
membranes. After blocking, the mem-
branes were incubated with ERmono-
clonal antibody as described in Materials
and Methods. B, ER immunostaining
in the PVN. Photomicrographs of the
PVN immunostained with the N-termi-
nus hER antibody (left panel) and the
N-terminus hER antibody pread-
sorbed with its specific peptide (right
panel) in OVX, oil-treated females.
Scale bar, 60 m.
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Characterization of ER and ER antibodies: ligand-bound
vs. unbound receptors
As some steroid receptors antibodies are preferential in
their binding to either the unoccupied (20) or the occupied
(26) form of the receptor, we compared the number of ER-ir
and ER-ir cells after a 20-min injection of 50 g 17-E2. The
number of ER-ir cells did not vary in any brain region 20
min after the injection of 50 g free 17-E2 (vehicle vs. E2: in
PvPO, 116  10.5 vs. 116.2  5.2; in BNSTpr, 178  15.1 vs.
178.2  16.8; in MEApd, 177.6  8.1 vs. 178.6  18.6), dem-
onstrating that the polyclonal ER antibody used in the
study recognizes both ligand-bound and unbound ER. In
contrast, immunoreactivity for ER was not detectable 20
min after treatment with 50 g free 17-E2 (vehicle vs. E2: in
PvPO, 43.2  6 vs. 0  0; in BNSTpr, 54  11.5 vs. 0  0; in
MEApd, 77.8  4.6 vs. 0  0), suggesting that ER immu-
nostaining is greatly affected by occupation of the receptor
with a saturating dose of free E2.
Neuronal distribution of ER-ir, ER-ir, and PgR-ir, and
their regulation by EB treatment
The pattern of distribution of ER-ir in oil- or EB-treated
female brains was consistent with previous reports (27–29).
ER-ir was present in nuclei of neurons of the preoptic area;
the PvPO; the principal and medial nuclei of the BNST; the
anterior, lateral and ventromedial hypothalamus; the par-
vocellular part of the PVN; the central, medial, and cortical
amygdala; the arcuate nucleus; the piriform cortex; and, to a
lesser extent, the hippocampus. The number of ER-ir neu-
rons in the MEApd and PVN significantly decreased 48 h
after EB treatment (P 0.05; Table 1). The number of ER-ir
cells did not vary in any brain region 2 h after treatment with
10 g EB vs. treatment with vehicle (oil vs. EB: in PvPO,
106.6 10.8 vs. 128.3 5.2; in BNSTpr, 208 7.9 vs. 181.4
40; in MEApd, 185.6 23 vs. 164 24.6), consistent with the
finding that occupancy of ER by E2 does not change the
interaction of the ER antibody, C1355, with ER. Therefore,
the decrease in ER-ir cells observed at 48 h is probably due
to down-regulation of ER by E2.
The distribution of ER-ir cells was consistent with the
expression patterns reported for ER mRNA (5) and protein
(19). The hER antibody used in this study specifically rec-
ognized recombinant ER protein by immunoblotting (Fig.
1A), and the immunostaining with this antibody was com-
pletely blocked by preadsorption of the antibody with the
peptide that it was generated against (Fig. 1B). In the fore-
brain, ER-ir was found in nuclei of cells in the PvPO, the
dorsal and ventral BNSTpr, the dorsal and magnocellular
part of the PVN, the anterior and caudal supraoptic nucleus,
and the anterior and posterodorsal MEA (Fig. 2). The number
of ER-ir cells significantly decreased in the PvPO and
BNSTpr 48 h after EB treatment vs. treatment (P  0.05;
Tables 1 and 2). Even though the level of E2-occupied ER
is probably higher at 2 h than at 48 h, the number of ER-ir
cells did not change in any brain region 2 h after treatment
with 10 g EB vs. treatment with vehicle (oil vs. EB: in PvPO,
49.3  13 vs. 59.3  15; in BNSTpr, 69  4.9 vs. 63.3  9.5;
in MEApd, 91.3  10 vs. 77.6  20). This suggests that the
dose of EB (10 g) used in the experiment did not interfere
with antibody binding to the receptor, even though a much
larger dose of free E2 (50 g) interfered with immunostain-
ing. Therefore, the decrease in ER-ir seen at 48 h represents
down-regulation of ER-ir by E2.
The distribution of PgR-ir in the brain of both oil- and
EB-treated female rats was more extensive than previously
reported (25, 30–32), because of greater sensitivity of the
immunostaining technique used here. No immunostaining
was observed with PgR-preadsorbed PgR antibodies (data
not shown). Many PgR-ir cells were detected in the preoptic
area, BNST, the lateral and ventromedial hypothalamus, the
arcuate nucleus, and, to a lesser extent, the parvocellular part
of the PVN. PgR-ir was also observed in the hippocampus,
the piriform cortex, various amygdala nuclei, the magnocel-
lular part of the PVN, and layers III–VI of the cerebral cortex
(data not shown). The number of PgR-ir neurons in the PvPO,
the BNSTpr, the MEApd, and the PVN did not differ between
oil- and EB-treated females (Table 2). However, E2 treatment
resulted in a significant increase (P  0.05) in staining in-
tensity (i.e. pixel density) of PgR-ir in the PvPO, BNSTpr, and
MEApd of EB-treated females (Table 3), consistent with pre-
vious findings that there is E2-independent PgR expression
throughout the brain, and that E2 can also increase PgR
levels.
Coexpression of ER-ir and ER-ir
Colocalization of ER-ir and ER-ir was observed in cells
of the PvPO, the BNSTpr, and the MEApd (Table 1 and Fig.
3). The number of neurons expressing both ER-ir and ER-ir
decreased significantly after EB treatment in the PvPO, BN-
STpr, and MEApd (Table 1). The percentage of ER-ir neu-
rons containing ER-ir in the PvPO and MEApd decreased
significantly in the EB-treated group compared with the oil-
treated group (P 0.05; Fig. 4A). Conversely, the percentage
of ER-ir neurons containing ER-ir in the MEApd de-
creased significantly in the EB-treated group compared with
the oil-treated group (P 0.05; Figs. 4B). In the PVN, because
ER-ir and ER-ir were in anatomically distant sites, very
TABLE 1. Coexpression of ER and ER in brain regions
Area Labeling Oil EB
BNSTpr ER-ir 377.8  23.1 365.8  60.5
ER-ir 128.4  22.3 50.8  10.6a
ER-ER-ir 80.7  5.9 52.8  5.2a
PvPO ER-ir 219.4  17.7 189.2  15.5
ER-ir 97.0  12.4 29.2  2.8a
ER-ER-ir 90.8  14.1 25.5  2.0a
MEApd ER-ir 549.0  24.0 361.8  59.9a
ER-ir 129.0  20.6 123.4  24.8
ER-ER-ir 90.0  14.0 38.2  9.3a
PVN ER-ir 72.6  16.1 35.2  7.1a
ER-ir 96.0  5.7 93.8  10.9
ER-ER-ir 3.4  1.3 2.2  1.3
The numbers (mean  SEM) of ER-ir-, ER-ir-, and ER-ER-ir-
containing neurons (cells per unit area; see Materials and Methods for
area of each brain region) in the BNSTpr, PvPO, MEApd, and PVN
of OVX rats treated for 48 h with oil (n 5) or EB (n 5) were counted
as described in Materials and Methods.
a Significantly different from oil group (by t test, P  0.05).
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little colocalization of ER-ir and ER-ir was observed (Table
1 and Fig. 4, A and B).
Coexpression of PgR-ir and ER-ir
Coexpression of PgR- and ER-ir was observed in cells of
the PvPO, the BNSTpr, the MEApd, and the PVN (Table 2).
The number of neurons coexpressing both PgR-ir and ER-ir
in all regions observed did not differ between groups (Table
2). The percentage of PgR-ir neurons containing ER-ir in the
PvPO decreased significantly in the EB-treated group com-
pared with the oil-treated group (P  0.05, Fig. 5A). In all
regions observed, there was no difference in the percentage
of ER-ir neurons containing PgR-ir between groups (Fig. 5B).
As in this experiment the PgR immunocytochemical pro-
FIG. 2. Distribution of ER-ir cells in female brain. AvPV, Anteroventral periventricular nucleus; SON, supraoptic nucleus. One small dot
represents 1 ER-ir cell; one large dot represents 10 ER-ir cells.
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cedure used was more sensitive than in previous work, ER-
independent PgR were also detected. To focus only on the
E2-induced PgR expression, we adjusted our criterion of
imaging PgR to eliminate ER-independent PgR-ir (see Ma-
terials and Methods). Upon counting only darkly immuno-
stained PgR cells in the EB-treated group by selecting an
upper threshold for pixel density as a mean of selecting only
E2-induced PgR-ir cells, it was observed that about 35%, 28%,
and 25% of PgR-ir neurons coexpressed ER-ir in the PvPO,
the BNSTpr, and the MEApd, respectively (Fig. 6).
Discussion
In the forebrain of female rats, ER-ir was coexpressed in
ER-ir- and PgR-ir-containing neurons. Furthermore, E2
treatment modulated the expression of ER, ER, and PgR
in a brain region-specific manner. This caused a change in the
ratio of cells coexpressing both ER subtypes or ER and PgR
in specific brain areas. Also as expected, E2 treatment in-
duced the expression of PgR in hypothalamic and limbic
regions, which occurred in part in ER-ir-containing neurons.
The hER antibody used in the present study appears to
be very specific for ER as assessed by immunoblotting and
immunoprecipitation assays. The antibody reacted with
ER, but not ER, PgR, or AR, by Western blot (Fig. 1A and
data not shown) and by the elimination of immunostaining
after antibody preadsorption with its specific peptide (Fig.
1B). Although the antibody recognized the ligand-bound
ER by in vitro immunoprecipitation assays using recombi-
nant proteins (data not shown), we found that sc treatment
of ovariectomized female rats with a large amount of free E2
(50 g) eliminated ER immunostaining in all brain regions.
This suggests that in brain tissue, this antibody does not react
with ligand-bound ER. Discrepancies between in vitro and
in vivo characteristics of antibodies have previously been
reported, such as for the specific ER antibody, H222 (20).
Although antibodies raised against the N-terminus of ER
were not reported to show differential interactions with ER
(20), this may not be the case for the ER antibody used in
these studies. Blocking of the ER antibody epitope by ligand
binding may occur in vivo through conformational changes
in ER upon binding of ligand, by dimerization of the re-
ceptor with ER or ER, or by interaction of ER with other
accessory proteins, such as cofactors.
The distribution of ER-ir (Fig. 2) as assessed with the
N-terminus hER monoclonal antibody was different from
that in previous studies in which a polyclonal C-terminal rat
ER antibody was used (19, 33). Using the C-terminal ER
antibody, fiber and cytoplasmic stainings were observed in
the lateral septum and the hippocampus (19), which were not
observed using the N-terminus ER antibody. In contrast to
the C-terminal antibody, which labeled cells in the lateral
septum, the medial BNST, the PVN, the supraoptic nucleus,
the anterior MEA, and the hippocampus (19), the N-terminal
antibody labeled numerous cells within the PvPO, the BN-
STpr, the PVN, the supraoptic nucleus, and the MEApd,
where the highest density of ER mRNA-containing cells
and the highest level of ER mRNA have been reported (5).
This suggests that the human N-terminus ER antibody used
in the present study may specifically recognize cells con-
taining moderate to high levels of ER. Thus, the extent of
colocalization of ERwith ER or PgR and the changes in the
ratio of steroid-containing cells after hormonal treatment
reported here may be underestimated. These should, of
course, be taken as relative indexes of colocalization and not
as absolute numbers. It is also possible that ER mRNA is
expressed at a higher level than ER protein. Differential
protein expression of ER variants that have been reported
in the brain (34) could also be an explanation for the differ-
ences in ER distribution observed between in situ hybrid-
ization and immunocytochemical approaches.
Little work has been reported on the hormonal regulation
of ER in the brain. Previous studies reported that E2 treat-
ment caused down-regulation of ER mRNA expression in
the PVN (35) and the MEA (36). Although we did not observe
a decrease in the number of ER-ir cells in the PVN or the
MEApd 48 h after EB injection, the number of ER-ir cells
decreased in the PvPO and the BNSTpr. This decrease is
probably due to down-regulation of ER in specific brain
regions. Although an injection of 50 g free E2 20 min before
perfusion interfered with ER antibody binding to ER, an
injection of 10 g E2 benzoate 2 h before perfusion resulted
in apparent levels of ER-ir not different from those observed
TABLE 2. Coexpression of PgR and ER in brain regions
Area Labeling Oil EB
BNSTpr PgR-ir 162.8  14.5 184.0  22.5
ER-ir 154.6  23.6 74.8  16.3a
PgR-ER-ir 51.6  15.0 37.2  10.0
PvPO PgR-ir 144.0  26.7 181.6  23.6
ER-ir 92.4  9.8 49.0  16.1a
PgR-ER-ir 72.2  10.6 46.0  17.3
MEApd PgR-ir 184.6  26.3 225.8  41.8
ER-ir 129.2  7.6 94.2  23.1
PgR-ER-ir 24.8  4.4 24.0  3.2
PVN PgR-ir 154.0  17.3 137.0  20.9
ER-ir 93.0  9.6 80.4  17.8
PgR-ER-ir 65.4  4.6 50.0  6.1
The numbers (mean  SEM) of PgR-ir-, ER-ir-, and PgR-ER-ir-
containing neurons (cells per unit area; see Materials and Methods for
area of each brain region) in the BNSTpr, PvPO, MEApd, and PVN
of OVX rats treated with oil (n  5) or EB (n  5) were counted as
described in Materials and Methods.
a Significantly different from oil group (by t test, P  0.05).
TABLE 3. E2 treatment increases PgR expression in brain regions
BNSTpr PvPO MEApd PVN
Oil 1,722.4  194 6,765.8  1,244 4,380.6  265 3,452.2  145
EB 5,300.4  438a 24,067.8  1,635a 5,285.2  189a 3,739.8  512
Pixel density per area (mean SEM) for PgR-ir labeled cells in the BNSTpr, PvPO, MEApd, and PVN of oil- (n 5) or EB-treated OVX female
rats (n  5).
a Significantly different from oil group (by t test, P  0.05).
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after vehicle treatment. This suggests that even though ER
immunostaining can be influenced by occupation of the re-
ceptor with a saturating dose of free E2 (50 g), exposure to
a low level of circulating E2 (10g EB) does not interfere with
the ER immunostaining. Thus, decreases in ER immuno-
staining observed after EB injection are probably due to
down-regulation of ER. Although this issue needs to be
further examined with molecular approaches, the present
results are consistent with reports of down-regulation of ER
mRNA in the brain (35, 36) and other tissues (37) after E2
treatment. Therefore, these findings suggest that ER protein
expression may be differentially regulated by E2 in various
regions of the brain.
Our observations on the presence of ER-ir in hypothalamic
and limbic regions, including the PvPO, the BNSTpr, the par-
vocellular part of the PVN, and the MEApd, agree with pre-
vious reports using various ER antibodies (27–29). E2 treat-
ment significantly decreased the number of ER-ir neurons in
the MEApd and the PVN. This decrease is also probably due to
a brain region-specific down-regulation of ER, as ligand bind-
ing did not influence ER-ir staining (with the C1355 antibody
used in this study) in any brain region. Moreover, these findings
agree with previous reports of down-regulation of ER or ER
mRNA in the brain after E2 administration (38, 39).
In vitro studies suggest that ER and ER may het-
FIG. 3. ER, ER, and PgR immuno-
staining in PvPO. Photomicrographs in
the PvPO of OVX, EB-treated females of
the same microscopic fields showing
ER-ir (A), and ER-ir (B), PgR-ir (C),
and ER-ir (D). Scale bar, 60 m.
FIG. 4. Colocalization of ER-ir and ER-ir in brain areas. Percent of
ER-ir cells containing ER-ir (A) and percentage of ER-ir cells
containing ER-ir (B) in the BNSTpr, the PvPO, the MEApd, and the
PVN of OVX, oil-treated (u) and EB-treated (f) females. *, Signifi-
cantly different from the oil group (by t test, P  0.05).
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erodimerize (10). For this heterodimerization to occur in the
brain, both ER and ER must be expressed in the same
neurons. Colocalization of ER-ir and ER-ir was observed
in neurons of the PvPO, the BNSTpr, the MEApd, as well as
the PVN. Depending on the region and the hormonal treat-
ment, this represented less than 40% of the ER-containing
cell population, but this represented over 60% of the ER-ir
neurons, except in the PVN where very little colocalization
was observed. Shughrue et al. (18) previously reported a
comparable, high level of ER cells coexpressing ER in the
PvPO, the BNST, and the MEApd when examining the co-
localization of ER mRNA and ER-ir. In contrast in the
present study because the number of ER-ir cells is lower
than the number of ER mRNA cells in the brain regions
observed, the levels of ER-containing cell coexpressing ER
are lower than those reported in the earlier study (18). Nev-
ertheless, these findings provide evidence that ER and ER
have the opportunity to interact in vivo intracellularly in a
small population of limbic and hypothalamic neurons. Fur-
thermore, it suggests that in these brain regions, transcrip-
tional regulation by E2 could occur via at least three classes
of cells: cells containing ER, ER, or both.
Because ER expression decreased in the PvPO after E2
treatment, the number of ER neurons containing ER de-
creased significantly. This decrease in neurons coexpressing
both ERs also results in an increase in the number of cells
expressing only ER-ir. In contrast to the E2-induced de-
crease in ER in the PvPO, in the MEApd ER expression
significantly decreased after E2 treatment, which induced an
increase in the number of cells expressing ER only. As
previously mentioned, ER and ER isoforms have the abil-
ity to form heterodimers (10, 34), which have different tran-
scriptional activities than ER homodimers (11). Together
with the present data, this further suggests that differential
regulation of ERs by E2 may lead to cells with different
profiles of E responsiveness in a brain region-specific manner.
The neural distribution of PgRs in females and the increase
in its expression by E2 in some brain regions have been
described extensively using a variety of techniques (30, 31,
40). In other immunocytochemical studies, a limited distri-
bution of PgR-ir has been observed in the brain due to the
sensitivity of the immunocytochemical procedure adjusted
so that either only cells in which E2-induced PgR-ir were
labeled (30) or only dark nuclear staining was observed (32).
Using a higher concentration of antibody than had been used
previously, we detected PgR-ir in neurons of regions previ-
ously described as containing E2-induced PgR, such as in the
PvPO, the preoptic area, the BNSTpr, the lateral ventrome-
dial hypothalamus, the arcuate nucleus and the MEApd, as
well as E2-independent PgR such as in the PVN and the
cerebral cortex (31, 41–43). The requirement of a higher con-
centration of antibody necessary to visualize PgR in the PVN
and the cortex suggests a lower abundance of the receptor in
these regions. Both isoforms of PgR (PgR-A and PgR-B) have
been detected in the brain (41). Although it has been sug-
gested that the expression of one of the two PgR isoforms
(PgR-B) has less dependence on E2 (41), the PgR antibody
used here recognizes both PgR isoforms and does not allow
us to discriminate the two. In accordance with previous
reports (30), E2 injection increased the expression of PgR-ir,
as seen in the present study by an increase in optical intensity
in the PvPO, BNSTpr, and MEApd, but no effect of E2 on PgR
expression was detected in the PVN. This finding agrees with
earlier ligand binding studies in which progesterone binding
was seen throughout the brain, but E2 treatments increased
PgR expression only in limited areas (44).
Although the coexpression of PgR and ER has been re-
ported in cell lines and human tumor cells (12, 45), we report
here the in vivo coexpression of PgR-ir and ER-ir in neurons
of the PvPO, the BNSTpr, the MEApd, and the PVN of female
rat brains. Depending on the region and the hormonal status
of the females, 20–50% of the PgR-ir cells coexpressed ER-ir.
Conversely in the PvPO and PVN, over 70% of the ER-ir
cells coexpressed PgR-ir, whereas only about 45% did in the
BNSTpr and the MEApd. It is well known that E2 induces the
expression of PgR in ER-containing cells of the female brain
(15, 46). In the present study E2-induced PgR-ir was mea-
sured by an increase in the intensity of PgR-ir. It is important
to note that ER-ir was found in cells containing E2-induced
PgR-ir (EB-treated) as well as cells containing E2-indepen-
FIG. 5. Colocalization of PgR-ir and ER-ir in brain regions. Per-
centage of PgR-ir cells containing ER-ir (A) and percentage of ER-ir
cells containing PgR-ir (B) in the BNSTpr, the PvPO, the MEApd, and
the PVN of OVX, oil-treated (u) and EB-treated (f) females. *, Sig-
nificantly different from the oil group (by t test, P  0.05).
FIG. 6. Colocalization of PgR-ir of high immunofluorescent intensity
with ER-ir-containing cells in the BNSTpr, the PvPO, and the
MEApd of OVX, EB-treated females.
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dent PgR-ir (i.e. in oil-treated rats) in all regions tested. More
specifically, about 30% of cells that showed an increased
expression of PgR-ir coexpressed ER-ir. We did not test for
the presence of ER in these cells. However, as mentioned
earlier, E2-induced PgR-ir is almost exclusively in ER-
containing cells (15), strongly supporting the idea that cells
with E2-induced PgR and ER-ir may also contain ER.
In ER-gene disrupted (ERKO) mice, E2 treatment in-
creased the expression of PgR mRNA in the PvPO (16) and
of PgR-ir in the MEApd as well as in the arcuate nucleus and
the lateral ventromedial hypothalamus (17). Although our
present data suggest the involvement of both ER and ER
in the regulation of PgR expression, future studies using
various steroid receptor gene-disrupted models will be
needed to further examine whether the induction of PgR
expression by E2 is mediated by ER variants, ER, or both.
It has recently been shown that ER plays a modest role,
if any, in the regulation of female sexual behavior. Indeed,
although sexual behavior is not impaired in ER gene-
disrupted mice, the duration of sexual receptivity in females
is extended compared with that in wild-type animals (47). On
the other hand, the brain regions in which ER-ir is present
are known to be involved in gonadal hormone regulation of
a variety of neuroendocrine systems. For example, the pos-
terior medial BNST (level equivalent to the BNSTpr) is in-
volved in the regulation of the CRH expression in the PVN
(48), the expression of which is regulated by gonadal hor-
mones. Likewise, in the supraoptic nucleus and PVN, ER
has been located in oxytocin- and vasopressin-containing
cells (33), which are involved in reproductive functions.
Our results demonstrated that ER is present in cells con-
taining other steroid receptors in brain regions that are of
importance in females, and they suggest that ER alone or in
combination with ER and/or PgR may participate in the
hormonal regulation of a variety of neuroendocrine func-
tions. Furthermore, our results suggest that E2 may play a
crucial role in regulating amounts of ERs ( and ) and PgRs
in cells in a brain-region specific manner, which may, in turn,
induce differential expression of relevant genes.
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